DNA methylation and nonsmall cell lung cancer

Anatomical Record

Volumn 294, Issue 11, 2011, Pages 1787-1795

  Lu, Fang ^a   Zhang, Hong Tao ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Diagnostics; DNA methylation; Hypermethylation; Hypomethylation; Lung cancer; MicroRNA; Prognostics; Therapeutics

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; APC PROTEIN; CELL CYCLE PROTEIN; CYCLIN D; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; EPIGALLOCATECHIN GALLATE; FRAGILE HISTIDINE TRIAD PROTEIN; HYDRALAZINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MG 98; MICRORNA; MITHRAMYCIN; MOLECULAR MARKER; PROCAINAMIDE; PROCAINE; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOBLASTOMA PROTEIN; UROKINASE; VASCULOTROPIN RECEPTOR; WNT PROTEIN; ZEBULARINE;

AGING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL DIVISION; CELL GROWTH; CELL INVASION; CELL MATURATION; CELL PROLIFERATION; CHROMATIN STRUCTURE; CHROMOSOME REARRANGEMENT; CIGARETTE SMOKING; CLINICAL PRACTICE; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; EPIGENETICS; EUKARYOTIC CELL; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC VARIABILITY; GENOME IMPRINTING; GENOMIC INSTABILITY; HETEROCHROMATIN; HUMAN; LUNG CARCINOGENESIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; REVIEW; RISK ASSESSMENT; RNA DEGRADATION; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TRANSPOSON; UPREGULATION; X CHROMOSOME;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS; PHENOTYPE; PROGNOSIS;

EID: 80054111424     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.21471     Document Type: Review

References (119)

1. Andreasen PA, Egelund R, Petersen HH. 2000. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57: 25-40.
2. Auerkari EI. 2006. Methylation of tumor suppressor genes p16(INK4a), p27(Kip1) and E-cadherin in carcinogenesis. Oral Oncol 42: 5-13.
3. Baylin SB. 2005. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 (suppl 1): S4-S11.
4. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. 2001. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10: 687-692.
5. Belinsky SA. 2005. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 26: 1481-1487.
6. Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG, March TH, Baylin SB. 2003. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 63: 7089-7093.
7. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG. 1998. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95: 11891-11896.
8. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, Grimes MJ, Harms HJ, Tellez CS, Smith TM, Moots PP, Lechner JF, Stidley CA, Crowell RE. 2002. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62: 2370-2377.
9. Bird A. 1992. The essentials of DNA methylation. Cell 70: 5-8.
10. Bird AP. 1986. CpG-rich islands and the function of DNA methylation. Nature 321: 209-213.
11. Bird AP, Wolffe AP. 1999. Methylation-induced repression-belts, braces, and chromatin. Cell 99: 451-454.
12. Boumber Y, Issa JP. 2011. Epigenetics in cancer: what's the future? Oncology (Williston Park) 25: 220-226, 228.
13. Brabender J, Usadel H, Danenberg KD, Metzger R, Schneider PM, Lord RV, Wickramasinghe K, Lum CE, Park J, Salonga D, Singer J, Sidransky D, Holscher AH, Meltzer SJ, Danenberg PV. 2001. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 20: 3528-3532.
14. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glockner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG. 2008. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358: 1118-1128.
15. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, Sultmann H, Lyko F. 2007. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 67: 1419-1423.
16. Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernandez-Piqueras J, Malumbres M. 2008. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13: 496-506.
17. Calin GA, Croce CM. 2006. MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
18. Chalitchagorn K, Shuangshoti S, Hourpai N, Kongruttanachok N, Tangkijvanich P, Thong-ngam D, Voravud N, Sriuranpong V, Mutirangura A. 2004. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 23: 8841-8846.
19. Chilukamarri L, Hancock AL, Malik S, Zabkiewicz J, Baker JA, Greenhough A, Dallosso AR, Huang TH, Royer-Pokora B, Brown KW, Malik K. 2007. Hypomethylation and aberrant expression of the glioma pathogenesis-related 1 gene in Wilms tumors. Neoplasia 9: 970-978.
20. Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, Li BF. 1997. Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 277: 1996-2000.
21. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Huang HJS, Petrelli NJ, Zhang XL, O'Dorisio MS, Held WA, Cavenee WK, Plass C. 2000. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24: 132-138.
22. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. 2000. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319.
23. Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baler K, Pfeifer GP. 2005. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 20: 645-663.
24. Dammann R, Takahashi T, Pfeifer GP. 2001. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene 20: 3563-3567.
25. Digel W, Lubbert M. 2005. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. Crit Rev Oncol Hematol 55: 1-11.
26. Eden A, Gaudet F, Waghmare A, Jaenisch R. 2003. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300: 455.
27. Endoh H, Yatabe Y, Shimizu S, Tajima K, Kuwano H, Takahashi T, Mitsudomi T. 2003. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. Int J Cancer 106: 45-51.
28. Esquela-Kerscher A, Slack FJ. 2006. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
29. Esteller M. 2006. The necessity of a human epigenome project. Carcinogenesis 27: 1121-1125.
30. Esteller M. 2007. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298.
31. Esteller M, Corn PG, Baylin SB, Herman JG. 2001. A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229.
32. Esteller M, Herman JG. 2002. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 196: 1-7.
33. Eulalio A, Huntzinger E, Izaurralde E. 2008. Getting to the root of miRNA-mediated gene silencing. Cell 132: 9-14.
34. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM. 2007. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104: 15805-15810.
35. Fazi F, Racanicchi S, Zardo G, Starnes LM, Mancini M, Travaglini L, Diverio D, Ammatuna E, Cimino G, Lo-Coco F, Grignani F, Nervi C. 2007. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 12: 457-466.
36. Feinberg AP. 2004. The epigenetics of cancer etiology. Semin Cancer Biol 14: 427-432.
37. Frey FJ. 2005. Methylation of CpG islands: potential relevance for hypertension and kidney diseases. Nephrol Dial Transplant 20: 868-869.
38. Fu H, Subramanian RR, Masters SC. 2000. 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40: 617-647.
39. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H, Jaenisch R. 2003. Induction of tumors in mice by genomic hypomethylation. Science 300: 489-492.
40. Goffin J, Eisenhauer E. 2002. DNA methyltransferase inhibitors-state of the art. Ann Oncol 13: 1699-1716.
41. Gopisetty G, Ramachandran K, Singal R. 2006. DNA methylation and apoptosis. Mol Immunol 43: 1729-1740.
42. Hammond EC, Seidman H. 1980. Smoking and cancer in the United States. Prev Med 9: 169-174.
43. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T. 2005. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65: 9628-9632.
44. He L, Hannon GJ. 2004. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531.
45. Heller G, Fong KM, Girard L, Seidl S, End-Pfutzenreuter A, Lang G, Gazdar AF, Minna JD, Zielinski CC, Zochbauer-Muller S. 2006. Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene 25: 959-968.
46. Heller G, Zielinski CC, Zochbauer-Muller S. 2010. Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev 29: 95-107.
47. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826.
48. Honorio S, Agathanggelou A, Astuti D, Dallol A, Schuermann M, Martinsson T, Maher ER, Latif F. 2001. Epigenetic inactivation of RASSF1A from the 3p21.3 region in human cancers and its potential use as a molecular marker for early detection of lung and other cancers. J Med Genet 38: S23.
49. Howard G, Eiges R, Gaudet F, Jaenisch R, Eden A. 2008. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 27: 404-408.
50. Jang SJ, Soria JC, Wang L, Hassan KA, Morice RC, Walsh GL, Hong WK, Mao L. 2001. Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res 61: 7959-7963.
51. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, Slack FJ. 2007. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67: 7713-7722.
52. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. 2005. RAS is regulated by the let-7 MicroRNA family. Cell 120: 635-647.
53. Jones PA, Baylin SB. 2002. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
54. Joseph B, Mamatha G, Raman G, Shanmugam MP, Kumaramanickavel G. 2004. Methylation status of RB1 promoter in Indian retinoblastoma patients. Cancer Biol Ther 3: 184-187.
55. Jurkowska RZ, Jurkowski TP, Jeltsch A. 2011. Structure and function of mammalian DNA methyltransferases. Chembiochem 12: 206-222.
56. Kashima T, Nakamura K, Kawaguchi J, Takanashi M, Ishida T, Aburatani H, Kudo A, Fukayama M, Grigoriadis AE. 2003. Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer 104: 147-154.
57. Kassis ES, Zhao M, Hong JA, Chen GA, Nguyen DM, Schrump DS. 2006. Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells. J Thorac Cardiovasc Surg 131: 298-306.
58. Kerr KM, Galler JS, Hagen JA, Laird PW, Laird-Offringa IA. 2007. The role of DNA methylation in the development and progression of lung adenocarcinoma. Dis Markers 23: 5-30.
59. Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH. 2006. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 66: 4049-4054.
60. Kim SJ, Kang HS, Chang HL, Jung YC, Sim HB, Lee KS, Ro J, Lee ES. 2008. Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer. Oncol Rep 19: 663-668.
61. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Williams NN, Kaiser LR, Croce CM. 2003. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer. Cancer Res 63:3352-3355.
62. Laird PW. 2003. The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253-266.
63. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, Weinberg RA, Jaenisch R. 1995. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81: 197-205.
64. Lantry LE, Zhang Z, Crist KA, Wang Y, Kelloff GJ, Lubet RA, You M. 1999. 5-Aza-2'-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model. Carcinogenesis 20: 343-346.
65. Lei Z, Liu RY, Zhao J, Liu Z, Jiang X, You W, Chen XF, Liu X, Zhang K, Pasche B, Zhang HT. 2009. TGFBR1 haplotypes and risk of non-small-cell lung cancer. Cancer Res 69: 7046-7052.
66. Lin RK, Hsu CH, Wang YC. 2007a. Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells. Anticancer Drugs 18: 1157-1164.
67. Lin ZW, Thomas NJ, Bibikova M, Seifart C, Wang YH, Guo XX, Wang GR, Vollmer E, Goldmann T, Garcia EW, Zhou LX, Fan JB, Floros J. 2007b. DNA methylation markers of surfactant proteins in lung cancer. Int J Oncol 31: 181-191.
68. Liu H, Liu W, Wu Y, Zhou Y, Xue R, Luo C, Wang L, Zhao W, Jiang JD, Liu J. 2005. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res 65: 7635-7643.
69. Liu Z, Li W, Lei Z, Zhao J, Chen XF, Liu R, Peng X, Wu ZH, Chen J, Liu H, Zhou QH, Zhang HT. 2010. CpG island methylator phenotype involving chromosome 3p confers an increased risk of non-small cell lung cancer. J Thorac Oncol 5: 790-797.
70. Liu Z, Zhao J, Chen XF, Li W, Liu R, Lei Z, Liu X, Peng X, Xu K, Chen J, Liu H, Zhou QH, Zhang HT. 2008. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer. Lung Cancer 62: 15-22.
71. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, Casado S, Suarez-Gauthier A, Sanchez-Cespedes M, Git A, Spiteri I, Das PP, Caldas C, Miska E, Esteller M. 2007. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 67: 1424-1429.
72. Mao L. 2001. Molecular abnormalities in lung carcinogenesis and their potential clinical implications. Lung Cancer 34 (suppl 2): S27-S34.
73. Matsubara H, Takeuchi T, Nishikawa E, Yanagisawa K, Hayashita Y, Ebi H, Yamada H, Suzuki M, Nagino M, Nimura Y, Osada H, Takahashi T. 2007. Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 26: 6099-6105.
74. Mazieres J, He B, You L, Xu Z, Jablons DM. 2005. Wnt signaling in lung cancer. Cancer Lett 222: 1-10.
75. McWilliams A, MacAulay C, Gazdar AF, Lam S. 2002. Innovative molecular and imaging approaches for the detection of lung cancer and its precursor lesions. Oncogene 21: 6949-6959.
76. Miyamoto K, Asada K, Fukutomi T, Okochi E, Yagi Y, Hasegawa T, Asahara T, Sugimura T, Ushijima T. 2003. Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene 22: 274-280.
77. Miyamoto K, Ushijima T. 2005. Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol 35: 293-301.
78. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. 2008. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-594.
79. Momparler RL, Ayoub J. 2001. Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 34 (suppl 4): S111-S115.
80. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG. 1999. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 96: 12754-12759.
81. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T. 1993. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 8: 1063-1067.
82. Palakurthy RK, Wajapeyee N, Santra MK, Gazin C, Lin L, Gobeil S, Green MR. 2009. Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression. Mol Cell 36: 219-230.
83. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA. 2000. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60: 5954-5958.
84. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. 2000. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. Br Med J 321: 323-329.
85. Pfeifer GP, Rauch TA. 2009. DNA methylation patterns in lung carcinomas. Semin Cancer Biol 19: 181-187.
86. Pulling LC, Divine KK, Klinge DM, Gilliland FD, Kang T, Schwartz AG, Bocklage TJ, Belinsky SA. 2003. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Res 63: 4842-4848.
87. Qureshi IA, Mehler MF. 2011. Advances in epigenetics and epigenomics for neurodegenerative diseases. Curr Neurol Neurosci Rep, DOI: 10.1007/s11910-011-0210-2.
88. Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Penas R, Sanchez JM, Moran T, Camps C, Massuti B, Sanchez JJ, Salazar F, Catot S. 2005. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol 23: 9105-9112.
89. Rauch TA, Zhong X, Wu X, Wang M, Kernstine KH, Wang Z, Riggs AD, Pfeifer GP. 2008. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci USA 105: 252-257.
90. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, Garate L, Barrios M, Castillejo JA, Navarro G, Colomer D, Prosper F, Heiniger A, Torres A. 2005. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24: 7213-7223.
91. Rountree MR, Bachman KE, Herman JG, Baylin SB. 2001. DNA methylation, chromatin inheritance, and cancer. Oncogene 20: 3156-3165.
92. Sekido Y, Fong KM, Minna JD. 1998. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1378: F21-F59.
93. Shi H, Wang MX, Caldwell CW. 2007. CpG islands: their potential as biomarkers for cancer. Expert Rev Mol Diagn 7: 519-531.
94. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. 2005. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5: 615-625.
95. Sulewska A, Niklinska W, Kozlowski M, Minarowski L, Naumnik W, Niklinski J, Dabrowska K, Chyczewski L. 2007. DNA methylation in states of cell physiology and pathology. Folia Histochem Cytobiol 45: 149-158.
96. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB. 2002. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31: 141-149.
97. Suzuki M, Yoshino I. 2010. Aberrant methylation in non-small cell lung cancer. Surg Today 40: 602-607.
98. Suzuki MM, Bird A. 2008. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 9: 465-476.
99. Szyf M, Pakneshan P, Rabbani SA. 2004. DNA methylation and breast cancer. Biochem Pharmacol 68: 1187-1197.
100. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T. 2004. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756.
101. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD, Gazdar AF. 2001. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 61: 4556-4560.
102. Toyooka S, Suzuki M, Maruyama R, Toyooka KO, Tsukuda K, Fukuyama Y, Iizasa T, Aoe M, Date H, Fujisawa T, Shimizu N, Gazdar AF. 2004a. The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer 91: 771-774.
103. Toyooka S, Suzuki M, Tsuda T, Toyooka KO, Maruyama R, Tsukuda K, Fukuyama Y, Iizasa T, Fujisawa T, Shimizu N, Minna JD, Gazdar AF. 2004b. Dose effect of smoking on aberrant methylation in non-small cell lung cancers. Int J Cancer 110: 462-464.
104. Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. 2002. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 21: 5450-5461.
105. Tsou JA, Shen LY, Siegmund KD, Long TI, Laird PW, Seneviratne CK, Koss MN, Pass HI, Hagen JA, Laird-Offringa IA. 2005. Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer 47: 193-204.
106. Ushijima T, Okochi-Takada E. 2005. Aberrant methylations in cancer cells: where do they come from? Cancer Sci 96: 206-211.
107. Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF. 2000. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 92: 1303-1307.
108. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261.
109. Wade PA. 2001. Methyl CpG binding proteins: coupling chromatin architecture to gene regulation. Oncogene 20: 3166-3173.
110. Wang X, Ling C, Bai Y, Zhao J. 2011. MicroRNA-206 is associated with invasion and metastasis of lung cancer. Anat Rec (Hoboken) 294: 88-92.
111. Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA, Jr., Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA. 2008. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 19: 1053-1059.
112. Werb Z. 1997. ECM and cell surface proteolysis: regulating cellular ecology. Cell 91: 439-442.
113. Wilson IM, Davies JJ, Weber M, Brown CJ, Alvarez CE, MacAulay C, Schubeler D, Lam WL. 2006. Epigenomics-mapping the methylome. Cell Cycle 5: 155-158.
114. Yamada Y, Jackson-Grusby L, Linhart H, Meissner A, Eden A, Lin HJ, Jaenisch R. 2005. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci USA 102: 13580-13585.
115. Yamamoto H, Toyooka S, Mitsudomi T. 2009. Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 63: 315-321.
116. Zhang HT, Chen XF, Wang MH, Wang JC, Qi QY, Zhang RM, Xu WQ, Fei QY, Wang F, Cheng QQ, Chen F, Zhu CS, Tao SH, Luo Z. 2004. Defective expression of transforming growth factor beta receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer. Clin Cancer Res 10: 2359-2367.
117. Zhao J, Liu ZY, Li WW, Liu X, Chen XF, Zhang HT. 2008. Infrequently methylated event at sites-362 to-142 in the promoter of TGF beta R1 gene in non-small cell lung cancer. J Cancer Res Clin Oncol 134: 919-925.
118. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. 2001. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61: 249-255.
119. Zochbauer-Muller S, Minna JD, Gazdar AF. 2002. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist 7: 451-457.